Skip to main content

June 2018, Vol 8, No 6

A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
By Phoebe Starr
Lung Cancer
June 2018, Vol 8, No 6
A burning question is whether immunotherapy combinations will further improve outcomes compared with checkpoint inhibitor therapy alone—and if so, which combinations will rise to the top. Read More ›
Combining Sorafenib and Transarterial Chemoembolization Extends Progression-Free Survival in Patients with Hepatocellular Carcinoma
By Wayne Kuznar
Gastrointestinal Cancers
June 2018, Vol 8, No 6
Sorafenib (Nexavar) in combination with transcatheter ­arterial chemoembolization (TACE) significantly improves progression-free survival (PFS), with no unexpected adverse results, compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), according to results from the phase 2 TACTICS clinical trial. Read More ›
New Clues to Mismatch Repair and PD-1/PD-L1 Status and Survival in Patients with Gastric or Esophageal Cancer
By Charles Bankhead
Gastrointestinal Cancers
June 2018, Vol 8, No 6
Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis. Read More ›
Adding Abiraterone to ADT May Decrease Resource Utilization in Castration-Naïve Prostate Cancer
By Wayne Kuznar
Prostate Cancer
June 2018, Vol 8, No 6
The addition of abiraterone acetate (Zytiga) to androgen-­deprivation therapy (ADT) did not increase medical resource utilization in patients with metastatic castration-naïve prostate cancer who participated in the multinational LATITUDE clinical trial. Read More ›
Financial Toxicity High in Patients with Gynecologic Cancer
By Meg Barbor, MPH
Gynecologic Cancers
June 2018, Vol 8, No 6
Approximately 25% of women with gynecologic malignancies cannot afford the cost of their medical care, according to a study presented at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›
Encourage Minority Patients with Ovarian Cancer to Participate in Clinical Trials
By Meg Barbor, MPH
Gynecologic Cancers
June 2018, Vol 8, No 6
Participation in clinical trials may help to overcome health disparities in the treatment of advanced or recurrent ovarian cancer, and minority patients should be encouraged to participate, said Khilen B. Patel, MD, Obstetrics & Gynecology Resident, Medical College of Georgia, Augusta University, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
By Phoebe Starr
Immunotherapy
June 2018, Vol 8, No 6
Chimeric antigen receptor (CAR) T-cell therapy has had excellent results in late-stage leukemia and varying degrees of success in some other hematologic cancers, but thus far, solid tumors have not responded to this therapy. Read More ›
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
By Phoebe Starr; Phoebe Starr
Breast Cancer, Breast Cancer
June 2018, Vol 8, No 6
Metastatic estrogen receptor (ER)-positive breast cancer responds well to anti-ER therapies, but eventually resistance occurs and the drugs fail to work. A new study presented at the 2018 AACR meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›

Page 1 of 2